Abbott Laboratories (ABT) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Abbott Laboratories (NYSE: ABT):

• 10/27/2026 – Abbott Laboratories was downgraded by Argus from “buy” to “hold”.
• 10/24/2026 – Abbott Laboratories was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/22/2026 – Abbott Laboratories had its price target lowered by Citigroup from $125.00 to $122.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Abbott Laboratories had its price target lowered by Royal Bank Of Canada from $130.00 to $125.00. They now have an “outperform” rating on the stock.
• 10/22/2026 – Abbott Laboratories had its price target raised by Wells Fargo & Company from $112.00 to $119.00. They now have an “overweight” rating on the stock.
• 10/22/2026 – Abbott Laboratories had its price target lowered by JPMorgan Chase & Co. from $120.00 to $118.00. They now have an “overweight” rating on the stock.
• 10/22/2026 – Abbott Laboratories had its price target lowered by TD Cowen from $135.00 to $118.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Abbott Laboratories had its price target lowered by BTIG Research from $134.00 to $125.00. They now have a “buy” rating on the stock.
• 10/22/2026 – Abbott Laboratories had its price target raised by Robert W. Baird from $121.00 to $123.00. They now have an “outperform” rating on the stock.
• 10/16/2026 – Abbott Laboratories had its “buy” rating reaffirmed by TD Cowen. They now have a $135.00 price target on the stock.
• 10/7/2026 – Abbott Laboratories is now covered by Barclays. They set an “overweight” rating and a $120.00 price target on the stock.
• 10/2/2026 – Abbott Laboratories was upgraded by Rothschild & Co Redburn from “neutral” to “buy”. They now have a $127.00 price target on the stock, up from $119.00.
• 9/18/2026 – Abbott Laboratories was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.

Abbott Laboratories Stock Up 0.1%

Shares of Abbott Laboratories stock opened at $110.58 on Wednesday. The stock’s 50-day moving average is $103.99 and its 200 day moving average is $101.74. Abbott Laboratories has a one year low of $81.97 and a one year high of $132.02. The firm has a market cap of $191.53 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 1.94 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. During the same period in the previous year, the company posted $1.30 earnings per share. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. Equities research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $0.63 dividend. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is currently 94.03%.

Insider Activity

In related news, EVP Mary Moreland sold 3,500 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total transaction of $406,000.00. Following the transaction, the executive vice president owned 100,791 shares in the company, valued at $11,691,756. The trade was a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by insiders.

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.